Index S&P 500
P/E -
EPS (ttm) -6.74
Insider Own 17.56%
Shs Outstand 863.67M
Perf Week 2.03%
Market Cap 7.82B
Forward P/E 4.92
EPS next Y 1.84
Insider Trans 0.01%
Shs Float 711.68M
Perf Month -17.03%
Income -5811.00M
PEG -
EPS next Q 0.36
Inst Own 61.29%
Short Float 11.65%
Perf Quarter -40.20%
Sales 145.53B
P/S 0.05
EPS this Y -28.35%
Inst Trans -0.06%
Short Ratio 3.81
Perf Half Y -56.21%
Book/sh 15.80
P/B 0.57
EPS next Y -35.41%
ROA -6.40%
Short Interest 82.91M
Perf Year -59.59%
Cash/sh 0.81
P/C 11.13
EPS next 5Y -
ROE -33.49%
52W Range 8.46 - 27.05
Perf YTD -65.30%
Dividend Est. 1.53 (16.88% )
P/FCF -
EPS past 5Y -
ROI -13.41%
52W High -66.51%
Beta 0.68
Dividend TTM 1.23 (13.58% )
Quick Ratio 0.31
Sales past 5Y 0.68%
Gross Margin 16.70%
52W Low 7.09%
ATR (14) 0.40
Dividend Ex-Date Aug 21, 2024
Current Ratio 0.65
EPS Y/Y TTM -75.58%
Oper. Margin 0.42%
RSI (14) 38.06
Volatility 3.95% 4.16%
Employees 331000
Debt/Eq 2.47
Sales Y/Y TTM 6.92%
Profit Margin -3.99%
Recom 3.05
Target Price 11.50
Option/Short Yes / Yes
LT Debt/Eq 2.18
EPS Q/Q 191.36%
Payout -
Rel Volume 0.79
Prev Close 9.02
Sales Surprise 1.14%
EPS Surprise -7.48%
Sales Q/Q 2.64%
Earnings Jun 27 BMO
Avg Volume 21.76M
Price 9.06
SMA20 -3.99%
SMA50 -13.77%
SMA200 -48.52%
Trades
Volume 17,249,578
Change 0.44%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-26-24 Initiated
Leerink Partners
Market Perform
$23
Feb-20-24 Downgrade
HSBC Securities
Hold → Reduce
Jan-03-24 Initiated
Barclays
Underweight
$21
Dec-22-23 Initiated
HSBC Securities
Hold
$27
Oct-23-23 Upgrade
JP Morgan
Neutral → Overweight
$27 → $30
Jul-03-23 Reiterated
Morgan Stanley
Underweight
$37 → $27
Jun-28-23 Downgrade
Deutsche Bank
Buy → Hold
$46 → $34
Feb-23-23 Initiated
Loop Capital
Buy
$45
Nov-23-22 Resumed
Morgan Stanley
Underweight
$39
Nov-22-22 Upgrade
Cowen
Market Perform → Outperform
$43 → $54
Nov-18-22 Upgrade
JP Morgan
Neutral → Overweight
$42
Nov-11-22 Upgrade
Deutsche Bank
Hold → Buy
Apr-01-22 Downgrade
Robert W. Baird
Outperform → Neutral
$70 → $51
Dec-16-21 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$56 → $49
Mar-25-21 Reiterated
Deutsche Bank
Hold
$49 → $55
Jan-11-21 Upgrade
Robert W. Baird
Neutral → Outperform
$55
Jan-11-21 Upgrade
Guggenheim
Neutral → Buy
$55
Jan-08-21 Resumed
Credit Suisse
Neutral
$42
Apr-06-20 Upgrade
UBS
Sell → Neutral
$49 → $44
Apr-03-20 Upgrade
Deutsche Bank
Sell → Hold
$51 → $43
Show Previous Ratings
Sep-17-24 11:30PM
04:08PM
Sep-16-24 01:21PM
10:40AM
07:52AM
(Pharmaceutical Business Review)
05:21AM
Loading…
05:21AM
Sep-15-24 07:15AM
06:26AM
Sep-14-24 11:22AM
02:17AM
Sep-13-24 08:48PM
(Associated Press Finance)
08:24PM
(The Wall Street Journal)
05:04PM
03:07PM
07:03AM
05:50PM
Loading…
Sep-12-24 05:50PM
04:22AM
Sep-11-24 04:07PM
Sep-10-24 04:23PM
12:00PM
09:45AM
Sep-09-24 09:00AM
08:30AM
Sep-06-24 05:45PM
04:52PM
06:52AM
Sep-05-24 05:50PM
04:15PM
09:00AM
09:00AM
08:19AM
Loading…
08:19AM
06:30AM
Sep-03-24 02:40PM
09:00AM
05:24AM
Aug-31-24 03:27PM
08:30AM
06:40AM
06:00AM
Aug-30-24 05:17AM
Aug-29-24 08:15AM
Aug-28-24 04:26AM
Aug-27-24 05:36PM
04:01PM
01:58PM
08:02AM
Aug-26-24 06:08PM
05:45PM
02:45PM
05:41AM
Aug-24-24 07:42AM
Aug-23-24 07:25AM
Aug-22-24 01:19PM
Aug-21-24 05:23AM
Aug-20-24 07:56AM
07:44AM
06:33AM
05:15AM
04:06AM
Aug-19-24 12:44PM
08:00AM
Aug-18-24 10:16AM
Aug-17-24 05:15AM
Aug-16-24 05:45PM
04:46PM
12:21PM
09:00AM
08:48AM
05:45AM
05:00AM
Aug-14-24 01:28PM
Aug-13-24 05:45AM
Aug-12-24 08:06AM
Aug-11-24 08:06AM
Aug-08-24 05:54PM
04:54PM
09:30AM
05:02AM
Aug-07-24 05:48PM
08:11AM
04:56AM
Aug-06-24 09:25AM
Aug-05-24 05:48PM
05:04AM
Aug-04-24 01:12PM
08:27AM
(Associated Press Finance)
Aug-02-24 12:51PM
12:00PM
11:51AM
08:52AM
(Associated Press Finance)
Aug-01-24 06:19PM
06:08PM
09:00AM
08:00AM
Jul-30-24 05:06AM
Jul-29-24 03:58PM
08:00AM
(Investor's Business Daily)
Jul-26-24 11:31AM
Jul-25-24 01:20PM
12:38PM
Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walgreens Boots Alliance, Inc. 10% Owner Sep 11 '24 Sale 11.13 11,619,998 129,330,578 23,239,996 Sep 13 07:04 PM Walgreens Boots Alliance, Inc. 10% Owner Aug 01 '24 Sale 240.56 4,438,171 1,067,646,416 19,980,000 Aug 05 06:44 PM Walgreens Boots Alliance Holdi Affiliate Aug 01 '24 Proposed Sale 244.46 3,398,929 830,902,183 Aug 01 08:56 PM Walgreens Boots Alliance, Inc. 10% Owner May 22 '24 Sale 215.12 1,859,390 400,000,158 24,418,171 May 24 04:05 PM Bhandari Inderpal S Director Apr 11 '24 Buy 18.05 3,000 54,150 3,000 Apr 15 05:45 PM Mahajan Manmohan EVP and Global CFO Apr 02 '24 Buy 19.38 6,000 116,280 166,969 Apr 02 06:40 PM Walgreens Boots Alliance, Inc. 10% Owner Feb 07 '24 Sale 235.41 4,212,395 991,639,907 26,277,561 Feb 09 07:00 AM JARRETT VALERIE B Director Jan 29 '24 Buy 22.44 4,456 99,993 4,456 Jan 31 04:11 PM SCHLICHTING NANCY M Director Jan 16 '24 Sale 23.05 15,209 350,567 0 Jan 18 04:18 PM WENTWORTH TIMOTHY C Chief Executive Officer Jan 05 '24 Buy 24.22 10,000 242,220 585,122 Jan 08 07:29 AM Gates Richard P. SVP, Chief Pharmacy Officer Nov 10 '23 Sale 20.45 1,000 20,450 73,929 Nov 14 08:22 PM Walgreens Boots Alliance, Inc. 10% Owner Nov 09 '23 Sale 195.38 1,279,590 249,999,896 30,489,956 Nov 14 07:15 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite